| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 185.71% | Craig-Hallum | → $20 | Initiates Coverage On | → Buy |
| 08/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/02/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 07/19/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 06/08/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/11/2023 | 185.71% | Maxim Group | $13 → $20 | Maintains | Buy |
| 05/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/23/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/27/2023 | 85.71% | SVB Leerink | $12 → $13 | Maintains | Outperform |
| 12/01/2022 | 257.14% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
| 11/10/2022 | 157.14% | HC Wainwright & Co. | $15 → $18 | Maintains | Buy |
| 11/10/2022 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Outperform |
| 10/21/2022 | 100% | Jefferies | → $14 | Assumes | → Buy |
| 10/11/2022 | 57.14% | SVB Leerink | $6 → $11 | Upgrades | Market Perform → Outperform |
| 08/02/2022 | — | Maxim Group | Initiates Coverage On | → Buy | |
| 05/17/2022 | -14.29% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 09/09/2021 | -14.29% | SVB Leerink | → $6 | Initiates Coverage On | → Market Perform |
| 11/30/2020 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Market Perform |
| 05/27/2020 | 42.86% | SVB Leerink | $12 → $10 | Maintains | Market Perform |
| 05/13/2020 | 114.29% | HC Wainwright & Co. | $13 → $15 | Reiterates | → Buy |
| 10/15/2019 | 85.71% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 01/30/2019 | -28.57% | Leerink Swann | $12 → $5 | Downgrades | Outperform → Market Perform |
What is the target price for scPharmaceuticals (SCPH)?
The latest price target for scPharmaceuticals (NASDAQ: SCPH) was reported by Craig-Hallum on September 7, 2023. The analyst firm set a price target for $20.00 expecting SCPH to rise to within 12 months (a possible 185.71% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for scPharmaceuticals (SCPH)?
The latest analyst rating for scPharmaceuticals (NASDAQ: SCPH) was provided by Craig-Hallum, and scPharmaceuticals initiated their buy rating.
When is the next analyst rating going to be posted or updated for scPharmaceuticals (SCPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of scPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for scPharmaceuticals was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating scPharmaceuticals (SCPH) correct?
While ratings are subjective and will change, the latest scPharmaceuticals (SCPH) rating was a initiated with a price target of $0.00 to $20.00. The current price scPharmaceuticals (SCPH) is trading at is $7.00, which is within the analyst's predicted range.